DPS to Design Two Facilities

| January 10, 2019

Boston – DPS Group, a privately owned global engineering, procurement, construction management, and validation firm serving high-tech process industries, has been selected to design two cGMP manufacturing facilities for Brammer Bio, a viral vector contract development and manufacturing organization that enables pharmaceutical and biotech innovators to translate proprietary gene therapy and gene-modified cell therapy technologies into novel treatments for patients through the development and manufacture of viral vectors.

Brammer engaged DPS Group to provide process architecture and engineering services for the design of commercial suites that produce multiple gene transfer vector products in support of late-stage clinical programs leading to commercial supply. 

Advanced gene therapy manufacturing suites are being designed in Cambridge and Lexington. Both projects have accelerated schedules and are expected to be complete in the first half of 2019.

DPS Group is designing an 8,000sf renovation of Brammer’s commercial cGMP facility in Cambridge. Part of a larger 66,000sf building, the new space will increase the number of commercial suites, providing additional capacity to produce treatments for a wider array of biotech companies.

Several upfront challenges were faced with this project, including designing the highly flexible and adaptable suites within the 8,000sf footprint and minimizing operational impacts to other production, office, and lab areas in the building during construction. The design of both upstream and downstream suites will support viral vector production using single-use technology for adherent and 2,000-liter suspension processes.

Designed for many different potential client scenarios, the highly efficient suite layouts will accommodate a variety of equipment requirements and provide Brammer with facility flexibility to operate several manufacturing processes for multiple products and scale. The work also includes modifications to the existing purified water and WFI systems.

In addition, DPS Group is providing detailed design services to assist Brammer in developing a new cGMP manufacturing and quality control (QC) operations facility in an existing building in Lexington.

As the company’s second commercial facility, the 35,000sf build-out will support cGMP viral vector manufacturing with an associated fill/finish area, QC/micro and process establishment (PE) scale-up lab space, and warehouse for both cGMP and general operations.

To address ceiling constraints for utilities in the existing structure, DPS is devising a new platform of interstitial ceiling space to support additional air handlers and chillers. The solution provides Brammer with infrastructure flexibility in the future.

Each of the production suites in the facility can be run in either upstream or downstream mode, with larger suites accommodating multiple trains in parallel. DPS Group’s design affiliate, TRIA, a partner-led architecture firm, is designing a 15,000sf office space as the second phase of the Lexington facility.

Tags: , , , , , ,

Category: All, Life Science

For more info on how to submit content or advertise with High-Profile, connect with us here!

Would you like more info on how to submit content or advertise with High-Profile?

 

Connect with us here!